This is topic PLRS...HUGE ALERT..STOCK TO WATCH..COMING OF BOTTOM in forum Micro Penny Stocks, Penny Stocks $0.10 & Under at Allstocks.com's Bulletin Board.
i am thinking of jumping soon....maybe
Posted by The surgeon on :
Wait until ARCA moves on. He still has a few more shares to get rid of and as you can see he is sitting * .023 This should reverse nicely when the selling is done
Posted by superman7 on :
starting to move again
.021(1) by .022(2)
Posted by superman7 on :
ARCA on bid now and all the way at .023 on the ask now
might be getting ready
Posted by The surgeon on :
good sign
Posted by The surgeon on :
Nice volume aswel!
Posted by atleast on :
***** pick for Monday
Posted by atleast on :
quote:Originally posted by atleast: ***** pick for Monday
l e b e d
Posted by The surgeon on :
Looks like they increased their shares recently. This is a great bottom play. Alot of people are getting in and waiting for the move before putting it out there. Been watching this like a hawk. It's getting close.
Posted by atleast on :
facts: 73,909,663 common shares issued and outstanding as of September 5, 2006
51,807,580 traded since 10/05/06
last "injection" - $470,000 grant from Israeli Government (PR from August 24,2006)
Should be *********** play (and only play, 10KSB looks scary - read snips from it below).
I'll watching it on Monday and probably will jump into on the first dip - so much pump is expected - you couldn't ignore the pressure...
from 10KSB: **** We have not generated any revenues and our operating activities have used cash resources of $2,179,209 for the fiscal year ended June 30, 2006. This negative cash flow is attributable to our operation expenses, including but not limited to, research and development expense and the payment of our audit fees and legal fees. We anticipate that our operating expenses will increase as we intend to conduct detailed development of our first product - hematopoietic stem cells, animal pre-clinical trials and experiments and clinical trials and work towards its completion. We estimate our expenses in the next twelve months will be approximately $2,600,000, generally falling in two major categories: research and development costs and general and administrative expenses. **** We do not expect to generate any revenues in the next twelve months. Our products will likely not be ready for sale for at least five years, if at all. ****
Posted by The surgeon on :
7 day support *.018. Hmmmmmmm
Posted by knicks321 on :
Pluristem Pre-Clinical Results: Placenta Expanded Cell Therapy Product Increases Umbilical Cord Blood Engraftment up to 500% in Bone Marrow Transplants
By BusinessWire Last Update: 10/16/2006 7:31:10 AM Data provided by
HAIFA, Israel, Oct 16, 2006 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (PLRS), a cell therapy company dedicated to the commercialization of stem cell products, announces promising final results of an animal model study which could benefit 100,000 blood cancer patients annually. PLX-I, the Company's innovative adjuvant cell therapy product is based on Placenta Expanded Mesenchymal cells. It intended to resolve the global shortfall of matched tissue for blood cancer patients requiring bone marrow transplantation by improving the engraftment of Umbilical Cord Blood (UCB). The Pre-Clinical results document that adding Pluristem's PLX-I to UCB stem cells during the Bone Marrow Transplant (BMT) human cell engraftment in NOD SCID mice showed up to a 500% increased engraftment after irradiation and Chemotropic treatment.
BMT traditionally treats patients whose bone marrow has been damaged by chemotherapy, or certain genetic diseases that lead to anemia, leukemia, lymphomas, autoimmune disease and other blood-related disorders. Its effectiveness is severely limited because of the lack of a matching donor or shortage of UCB stem cells engrafted during the procedure. If additional animal studies and human clinical trials prove equally successful as this first Pre-Clinical, Pluristem's PLX-I product with 500% increased engraftment could lead to more Bone Marrow Transplants (BMT) for these types of blood cancers.
The animal studies were performed on immune-deficient NOD SCID mice following systemic myeloablation of their bone marrow to simulate the BMT clinical protocol. This in-vivo model is based on the known ability of human Hematopoietic Stem Cells (HSC) to engraft in mouse bone marrow and to simulate the recovery of the human's Hematological system. 50,000-100,000 human UCB derived CD34+ cells (hUCB CD34+) were injected into the tail vein of NOD-SCID mice along with 0.5*106 PLX I cells. After periods of 28-32 days, mice were sacrificed and the marrow was analyzed. Human cell engraftment was performed in both sub lethally irradiated (350 Rad) and chemotherapy administrated (50 mg/kg Busulfan) mice. FACS analysis of human CD45 positive cells in mice bone marrow demonstrated an increscent of cell engraftment in part of the experimental animals up to 5 folds compared to mice transplanted with CD34+ cells only.
Mr. Zami Aberman, CEO, stated, "Co-transplantation of PLX-I cell types may be a promising manipulation improving cord blood performance during the bone marrow transplants in adults blood disorder. The pre-clinical results suggest blood disorder treatment is being improved by using MSC derived from placenta and expanded in Pluristem's 3D bioreactor in combination with UCB derived HSC. We strongly believe that PLX-I can change the clinical process now being used to treat blood cancer and could eventually save millions of lives."
About Pluristem
Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product targets a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include statements: results of our animal model study could benefit 100,000 blood cancer patients annually; that PLX-1 is intended to resolve the global shortfall of matched tissue for blood cancer patients requiring bone marrow transplantation by improving the engraftment of Umbilical Cord Blood (UCB); that if additional animal studies and human clinical trials prove equally successful as this first Pre-Clinical, Pluristem's PLX-I product with 500% increased engraftment could lead to more Bone Marrow Transplants (BMT) for these types of blood cancers; the pre-clinical results suggest blood disorder treatment is being improved by using MSC derived from placenta and expanded in Pluristem's 3D bioreactor in combination with UCB derived HSC; and we believe that PLX-I can change the clinical process now being used to treat blood cancer and could eventually save millions of lives. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that pre-clinical trials results may not be able to be successfully duplicated in clinical trials; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
SOURCE: Pluristem Life Systems, Inc.
Posted by knicks321 on :
theres the news we need to get this baby moving off its bottom!!!!
Posted by mrinos on :
I am not in this one, but has an awesomely respectable chart. It is holding STRONGGGGGG
Posted by before_the_crowd on :
Very Interesting...Chart.. Volume Huge but not much movement today.... Gotta look into it....
Posted by atleast on :
quote:Originally posted by before_the_crowd: Very Interesting...Chart.. Volume Huge but not much movement today.... Gotta look into it....
CDs have to be covered - think almost done... Another day with 30-40 million and it will take off...
Posted by The Green Demon on :
Be careful...look at accum/dist
Posted by next1 on :
It looks like we are taking off finally !!!
Posted by superman7 on :
yeah looks like we are finally running...this is at a real bottom if it does take off it should be a huge run imo
Posted by next1 on :
I've heard this can be the next ten bagger
Posted by superman7 on :
it wouldnt surprise me
Posted by next1 on :
nice pull back, a chance to buy some more
Posted by superman7 on :
huge huge huge runner...here she goes!
Posted by superman7 on :
i think we will see .05 very soon as soon as tommorow
Posted by atleast on :
quote:Originally posted by atleast:
quote:Originally posted by before_the_crowd: Very Interesting...Chart.. Volume Huge but not much movement today.... Gotta look into it....
CDs have to be covered - think almost done... Another day with 30-40 million and it will take off...
with an additional 20 million in trades CDs will be wiping out... Even with 50% of mirror trades 4.5 - 5 cents to EOW look highly positive... eom
Posted by superman7 on :
here comes .03
Posted by superman7 on :
.03 is gone! that was fast a wall of 12 mms fell in like 1-2 min lol
this is huge
Posted by superman7 on :
just doubled up my position at .029
Posted by superman7 on :
here is some PLRS i found on another message board:
kirkdog7: PLRS is going to become the biggest play in the entire OTC BB market!!!!!!!!!!!
The US Government just came out yesterday and said they are earmarking $14 million for umbilical cord blood banks because they believe it will cure blood cancer and save millions of lives.
In order for the umbilical cord blood to take the place of Bone Marrow Transplants, you need PLRS's technology!!!!!!!!!
BUZZ!!! kirkdog7: PLRS=50 million served today! and the day is still young! BUZZ!!! kirkdog7: smart--gonna make BANK !!! kirkdog7: .028 X .028 now kirkdog7: something BIG supposed to happen FRIDAY kirkdog7: .029 X .029 and watch for Friday kirkdog7: more than a 3-day tour!! could be a life changer!!! ggg ggg: agreed kirkdog7: 67 million already served today!!!!!!!!!!!!
Posted by superman7 on :
this volume today is a record for PLRS
Posted by superman7 on :
here comes .03 again
this ones is so strong
Posted by superman7 on :
ARCA just moved to .0299!!!!! here comes the run IMHO
Posted by next1 on :
A nice new candle we have for the day!
Posted by superman7 on :
EOD run is starting NOW
.0281 by .0285
Posted by next1 on :
We could not ask for a better looking chart, we broke the 50 day moving average on incredibly strong volume today. Considering we are coming of the bottom we must be setting up for a very nice run.
Posted by dmxbr9 on :
next resitance is about .038 area, after that we are smooth sailing. This will open over .03 in the am... i smell news 2
Posted by weatherbill on :
watch tomorrow, this move by the tenths of a penny and no long by the hundreths as it has been doing. It will be a clear sign that the debenture selling is over and this thing is about to move much quicker.
and I agree. I bet ***** and PLRS has something up theri sleeve for friday to move the PPS up big!
Posted by brooklynboyz84 on :
We all know this is a ***** pick right??Not saying stock is bad,just be aware of what his picks always do ok?
Posted by Schwabie on :
S H A K E R Z Z Z IS ON THIS...
HES HARD AT WORK AT IT SINCE .022
FAST RISE EVEN HARDER FALL.
Posted by Schwabie on :
BTW,
I AM NOT SAYING THIS CAN'T RUN, IT HAS LOTS OF POTENCIAL
JUST... PROTECT YOUR INVESTMENT !!!!
Posted by knicks321 on :
so whats the deal is anyone playing this today?
Posted by superman7 on :
yes there is one person Posted by superman7 on :
its gapping.
.0286(1) .029(3)
shakerzzz is on this??? yeah u are right i just checked i honestly never even knew i dont really follow him that much, cause in this bad market even he cant do to much but i still think this one will run cause its being fueled with tons of rumors, which usually makes stocks run, also this is a bottom player with huge volume and intrest coming in....could be alot of shorts!
Posted by superman7 on :
.0297(2) by .0298(2)
Posted by superman7 on :
.03 should be falling very soon
only 2 mms left till there
Posted by Fuzzy1018 on :
they walked it down after the great open this morning; goin' back up now huge news out today
Posted by superman7 on :
.0294(1) by .0294(1)
lets see the .03's already!
Posted by superman7 on :
PLRS-Upon FDA approval, PLRS's new facilities could support production and shipping of up to 50 doses of PLX-I per day worth more than $500,000.
That would be $182,500,000 in revenues per year!!! 50 doses a day would be for 18,250 patients per year when there are between 105,000 and 125,000 patients that are untreated annually because they cannot find a Bone Marrow Transplant match.
THIS STOCK WILL BE HUGE!!!
Posted by superman7 on :
PLRS gonna fly/insider buying in Jan 06 *.1
Posted by Fuzzy1018 on :
PLRS NEWS 0.0280 Pluristem Upgrades Manufacturing Facilities to Enable Production of First Biological Product for Phase I Clinical Trials
Wednesday, October 18 2006 7:30 AM, EST
HAIFA, Israel --(BUSINESS WIRE)-- Pluristem Life Systems, Inc. (OTCBB: PLRS) announces they have completed upgrading and restructuring their manufacturing facilities to enable the production of their first biological product PLX-I for Phase I clinical trials. The manufacturing facilities include thirteen units of 7000 square feet total and include five clean room units of 3000 square feet total. Upon FDA approval, the facilities could support production and shipping of up to 50 doses of PLX-I per day worth more than $500,000 . Zami Aberman, Pluristem CEO states, "PLX-I can be used for the treatment of blood disorders and it could also be helpful in additional clinical indications like autoimmune disorders or cardiovascular diseases. It is a very valuable product and we have made a strategic decision to control the production in-house. Handling the product ourselves gives us a distinct advantage when these cross application situations arise. And we have further determined that to assist us in successful Phase I clinical trials and the ultimate approval by the FDA, we have upgraded and restructured as a GMP Compliance facility. GMP Compliance is a set of regulations set forth by the FDA to help ensure that various products for human use are safe and effective. GMP regulations address sanitation, process validation, equipment and document traceability, and personnel qualification. We are also working to become completely GMP compliant to further assure the future successful production and market acceptance of PLX-I." About Pluristem Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations. www.pluristem.com
Safe Harbor Statement This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include statements: that our facilities enable the production of the first biological product PLX-I for Phase I clinical trials; that our facilities could support production and shipping of up to 50 doses of PLX-I per day worth more than $500,000 per day, that PLX-I can be used for the treatment of blood disorders and it could also be helpful in additional clinical indications like autoimmune disorders or cardiovascular diseases, that we intend to control the production ourselves; that our production will give us a distinct advantage; that we are working to become completely GMP compliant; that we expect our first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation, and our first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unable to attain GMP compliance; our facilities may not be capable of controlling production; we may not receive any orders for our products; we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC. Source: Pluristem Life Systems, Inc.
Posted by superman7 on :
the .03 wall as fallen, now lets work on the .04 wall
i think we can see about .08 easy this week
alot of rumors going around on this one, with alot of news.
Posted by Fuzzy1018 on :
hard to get a fill right now even at ask
Posted by superman7 on :
.0308(3) by .0309(1)
Posted by superman7 on :
volume is already at 30 mil!
Posted by Fuzzy1018 on :
with the FDA approval they'll be making $500,000/day wow
Posted by superman7 on :
.0313(1) by .0314(3)
Posted by Schwabie on :
LOOKS GOOD. WAITING FOR DIP.
I'M GOING IN FOR A FEEW SHARES.
Posted by superman7 on :
here comes the little dip...then back to a new HOD very soon
Posted by superman7 on :
ok looks like we are headed back up to a new HOD
.0307(2) by .031(2)
Posted by superman7 on :
sharp pullback but i still think we go up
Posted by Schwabie on :
IN AT .03 FOR A LIL ITTI BITTY BITE...
WE'LL SEE.
Posted by superman7 on :
notice how much thinner the ask side is getting..this one is really getting ready to take off!!
Posted by Fuzzy1018 on :
trying to create a panic by takin' it down with all the buying pressure coming in
Posted by superman7 on :
getting beat up right now, but notice how the ask side is pretty thin, before it was super thick mms everywere, this makes me think that when its done dipping it will move up now alot faster, and i think dilution is about done now, and this one is ready, plus there are tons of rumors and news and volume.
.0292 by .0296
THIS IS READY IMHO
Posted by superman7 on :
ARCA looks more like the buyer now then the seller, he keeps poping on the bid and far away on the ask!
Posted by superman7 on :
03's back up!
Posted by dmxbr9 on :
Im accuming as much as i can in the next few days, i smell more huge news. ImO this is gonna be trading in the .20 area real soon...
Posted by Fuzzy1018 on :
goin' up strong, possible news tom. after the meeting
Posted by BULListic on :
Back on its way up....***** PUMP coming soon to a gas station near you Posted by next1 on :
quote:Originally posted by BULListic: Back on its way up....***** PUMP coming soon to a gas station near you
This is not a pump, it's all about stem cells. Stem cells save a lot of lives. It saved my own life recently; I simply would not be here today without it. And now it's about to save a lot of wallets as well. So, if you think this is just a pump well, move on and don't bother us on this board will you!
Pluristem Pre-Clinical Results: Placenta Expanded Cell Therapy Product Increases Umbilical Cord Blood Engraftment up to 500% in Bone Marrow Transplants Monday October 16, 7:31 am ET HAIFA, Israel--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB: PLRS - News), a cell therapy company dedicated to the commercialization of stem cell products, announces promising final results of an animal model study which could benefit 100,000 blood cancer patients annually. PLX-I, the Company's innovative adjuvant cell therapy product is based on Placenta Expanded Mesenchymal cells. It intended to resolve the global shortfall of matched tissue for blood cancer patients requiring bone marrow transplantation by improving the engraftment of Umbilical Cord Blood (UCB). The Pre-Clinical results document that adding Pluristem's PLX-I to UCB stem cells during the Bone Marrow Transplant (BMT) human cell engraftment in NOD SCID mice showed up to a 500% increased engraftment after irradiation and Chemotropic treatment.
Posted by Doctoall on :
Bump
Posted by shortsqueezer on :
I bought 1 million on friday before close Posted by PlayBunny21 on :
PLRS last week traded 317.8 million shares!!!
It was the most active stock last week and I believe it could become the biggest percentage gainer this week!!!
PLRS finished Friday strong up $0.002 to $0.026.
So many eyes are on PLRS right now!!! Once we break through $0.03 again, this could EXPLODE!!! Monday could be the day!!!!!!
I believe that PLRS will have to file an 8-K this week disclosing that their convertible debentures have been converted.
This will be a major event for shareholders because it will show the investment community that PLRS's debt has been eliminated and there will no longer be a lot of selling pressure on the stock.
PLRS's CEO estimated in my meeting with him Thursday that there are now 240 million shares outstanding after the conversions. This would give PLRS a market cap of only $6.2 million at the current price.
When the convertible debenture agreement was announced on April 3rd, PLRS was trading for $0.08. Now that the selling pressure is gone, I believe we will see PLRS rebound to these levels very quickly.
We could go to $0.08 this week even if we trade just a small fraction of the volume we did last week.
I believe PLRS deserves to be valued substantially higher than $0.08.
Even a price of $0.20 would still give PLRS a market cap of less than $50 million.
PLRS could capture a significant share of the $5 billion commercial bone marrow transplant market.
You cannot put a price on the 105,000 - 120,000 lives PLRS could potentially save each year of blood cancer patients who can't find a matching bone marrow donor.
PLRS's PLX-I will provide for a superior alternative to the standard procedure of bone marrow transplantation using adult stem cells from umbilical cord blood.
Watch PLRS like a hawk this week!!!!! This could become the biggest winner of our lives!!!!!
Posted by onemorehit on :
I am definitely in first thing Monday morning! I have been watching this sub-penny gem for a while now and I think it is the right time to get onto the stem cell train.
Posted by PlayBunny21 on :
I got in ETIM on sharkster recommendation .
Now ***** and sharkster and a few other groups jumpin in on PLRS on monday. www.thesharkster.8m.com is the site , i cant wait to see what happens
Posted by PlayBunny21 on :
There is reason for PLRS to go higher with the recent news and upcoming presentation at Bio Europe. Most notably, the 424B4 filing reveals that 1/3 of the shares recently registered are underlying purchase warrants at 0.075 and 0.077 per share.
The company will receive the proceeds from the exercise of these warrants free and clear and has every incentive to do so, whereas the proceeds from the resale of common stock went to the selling security holders, removing overhanging debt. Fullfilling the obligations to the CD holders was the first step in setting the stage to move forward. Once PLRS reaches the 0.10 area, approximately $4,349,881.00 will be added to the company's working capital, as per the filing I will make referrence to.
This would be where many would expect the PPS to head towards, based on how these financings work. The timing of recent news and upcoming presentations suggests that this financing is being well executed.
When reading the disclaimers from Shazaam and *****, we see that they were not compensated by the company itself, but by one of the selling security holders, Zegal & Ross Capital, a total of $50k cash and no shares. The filings reveal that Zegal & Ross only directly hold 1.4 million shares. Since ***** wasn't compensated in shares, he has little reason to keep promoting PLRS unless he has reason to believe it's going much higher. He is putting his reputation and livelihood at stake.
Ask yourselves how high PLRS would need to go to make money on 1.4 million shares after paying out $50k.....The answer is it would have to be a multi bagger from here.
The options granted to management are at 0.10 per share indicating we won't see any sales from then for quite some time. There will be many alerts and talk about PLRS in the coming weeks, and it has been hinted there will be some good news coming from them in the very near term. We will see targets and chatter, but the important indicators are in the filings.
Posted by PlayBunny21 on :
Dr. Gyan Parida, Chairman, Global Venture Congress commented, "We are pleased to feature Pluristem as one of our presenting companies at the Global Venture Congress. We consider Pluristem a company that is imminently fundable. They were chosen to be a featured presenting company because of their novel technology, history of raising private capital, and their ability to maximize the capital raised by bringing adult stem cells to the Phase I/II development stage. Very impressive and commendable, Pluristem has passed our rigorous screening process."
Posted by Biotechnical on :
PRIZE TARGET this week ----- 0.05 ?
Posted by Biotechnical on :
Gapper on Monday !!!! BUY early and HOLD STRONG !!!!!!!
Posted by PlayBunny21 on :
It is unbelievable PLRS is trading for only $0.026!!!
PLRS has millions in cash and after the recent conversions they now have no debt!!!
PLRS's CEO estimates PLRS now has 240 million shares outstanding giving it a market cap of only $6.2MM. PLRS's CEO believes it will become a BILLION dollar company one day.
PLRS was the most active stock in the entire market last week and look how strong it closed on Friday!!!
Bone marrow transplants are needed for those suffering from leukemia, lymphoma, myeloma and many other hematological diseases. Unfortunately, 105,000 to 120,000 patients die each year because they can't find a matching bone marrow donor.
PLRS's technology could potentially save millions of lives. PLRS's PLX-I has been shown in preclinical trials to increase the engraftment of stem cells from umbilical cord blood by up to 500% in mice.
PLRS is now positioned to begin Phase I clinical trials and could change the clinical process now being used to treat blood cancer. PLRS's PLX-I could allow umbilical cord blood transplants to replace the bone marrow transplants that are used today.
The Israeli government realizes how huge PLRS could become and recently gave the company a $470,000 grant.
The US government also realizes the potential for umbilical cord blood to cure many diseases and just last week announced that they will award about $14 million to public cord blood banks around the country to increase the supply of cord blood donations from 50,000 to 150,000.
The timing couldn't be more perfect for PLRS!!!
So many eyes are on PLRS right now!!! PLRS could EXPLODE this week!!!
Posted by Biotechnical on :
PLRS BIG GAP TOMORROW !!!!
Posted by dmxbr9 on :
over .03 in no time...
Posted by Schwabie on :
GETTING SOME HITS...
Today’s Price Performance as of 10:30am EDT, 10/23/2006 Option Chains Margin Requirements Interactive Chart
Loading Chart1 Day | 5 Day | 6 Mo | 1 Yr | 3 Yr | 5 Yr $0.029 Last Price 0.0030 +11.54% Today’s Change $0.03 Today’s Open 10,774,781 Above Avg. Today’s Volume
Posted by bigpoppa on :
not bad i like what i see!!!!!!!!!!!!!!!!
Posted by bigpoppa on :
closed up 11.54% very good day
Posted by superman7 on :
wonderful close
.029!!
looks sweeeeeeeet for tommorow
i think it will be a big runner tommorow
we will see
Posted by dmxbr9 on :
i bet we see really big news this week...
Posted by bigpoppa on :
Fingers crossed for the big news this week!
Posted by superman7 on :
Press Release Source: Pluristem Life Systems, Inc.
Pluristem Completes the Conversion to Common Stock of 98% of the $3,000,000 in Convertible Debentures Issued on April 3, 2006 Tuesday October 24, 9:00 am ET
HAIFA, Israel--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS - News) announces they have completed the conversion of 98% of the $3,000,000 in convertible debentures that were issued on April 3, 2006 to common stock of the company. The outstanding common shares are now about 254 million shares. ADVERTISEMENT
Zami Aberman, Pluristem CEO states, "This allows us considerably more financing flexibility because until over 75% of the debentures were converted to common stock, we were prevented from pursuing certain types of financing arrangements and our assets were encumbered as collateral security for repayment of the debentures. Now that the vast majority of the debentures have been converted our assets are no longer encumbered and we are no longer restricted in the type of financing arrangements we can make. In addition, our balance sheet no longer will show the converted debenture proceeds as a liability."
About Pluristem:
Pluristem Life Systems, Inc. is a life-sciences-driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include statements: that PLX-I can be used for the treatment of blood disorders ; that we expect our first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation, and our first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
Contact: Emerson Gerard Associates, Inc. Jerry Jennings, Media Contact, 561-881-7318 mediareply*emersongerard.com
-------------------------------------------------------------------------------- Source: Pluristem Life Systems, Inc.
Posted by superman7 on :
this one should be very nice on the news
already gapping in pre-market
.0298(2) by .299(3)
we will eacily be over .03 before the market begins imo
Posted by superman7 on :
PLRS...the .03's are breaking right now on this news!
Posted by bigpoppa on :
Hey superman7 do you see this going to .05 this week????
Posted by atleast on :
from 8-K (Oct 24th at 13:40)
"On October 24, 2006 we announced that over 98% of the $3,000,000 in convertible debentures that we issued on April 3, 2006 have been converted to common stock in our company. This allows us considerably more financing flexibility because until over 75% of the debentures were converted to common stock, we were prevented from pursuing certain types of financing arrangements and our assets were encumbered as collateral security for repayment of the debentures. Now that the vast majority of the debentures have been converted our assets are no longer encumbered and we are no longer restricted in the type of financing arrangements we can make. In addition, our balance sheet no longer will show the converted debenture proceeds as a liability."
What the f*** "considerably more financing flexibility" means? More CDs in the nearest future? Is this the reason of PPS drop or just because l e b e d stops pump it?
Posted by bigpoppa on :
looks like its dipping
Posted by Biotechnical on :
40 million volume ''' 4 milllion Dollar trade !!!
Posted by dmxbr9 on :
we see better news soon imo
Posted by bigpoppa on :
hey dmxbr9 are you holding?
Posted by next1 on :
new out!
Posted by next1 on :
Dutton Associates Announces Investment Opinion: Pluristem Life Sciences Rating Raised to Speculative Buy by Dutton Associates Business Wire - October 25, 2006 09:58
EL DORADO HILLS, Calif., Oct 25, 2006 (BUSINESS WIRE) -- Dutton Associates updates its coverage of Pluristem Life Sciences (OTCBB:PLRS) raising its rating to Speculative Buy with a $.06 price target. The research note by Dutton senior analyst William R. Prather, R.Ph., M.D. is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
Pluristem Life Systems, Inc. stock overhang from a previous overhang has been worked through and the common stock could now significantly appreciate as this selling pressure is reduced. Because we continue to be enamored by Pluristem's technology we have, therefore, revised our investment rating to Speculative Buy with a 12-month price target of $0.06.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 31 senior analysts are primarily CFAs and have expertise in many industries. Dutton Associates provides continuing analyst coverage of over 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $20,000 from the Company for 2 Research Reports with coverage commencing on 9/06/2006. We do not accept payment of our fees in company stock. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
SOURCE: Pluristem Life Systems, Inc.
Dutton Associates John M. Dutton, President, 916-941-8119
Posted by bigpoppa on :
those Dutton and Associates guys know what there talking about, Im holding, Hopefully sooner or later it will pay off
Posted by Fuzzy1018 on :
great opportunity to get in here; big volume coming in should go back up
Posted by Fuzzy1018 on :
bouncing
Posted by Fuzzy1018 on :
any1 in on this one?
Posted by bigpoppa on :
Im still in this one fuzzy, its been dipping lately, do you think we'll get some news soon?
Posted by Fuzzy1018 on :
and we're off to the races
Posted by MEMY SELFANDI on :
Submarine races !
Posted by Fuzzy1018 on :
PLRS - .019 PLURISTEM LIFE SYSTEMS
Pluristem Expects to Submit Pre-IND Document to FDA by End of 2006 10/31/2006
HAIFA, Israel, Oct 31, 2006 (BUSINESS WIRE) -- Pluristem Life Systems, Inc. (OTCBB: PLRS), a cell therapy company dedicated to the commercialization of stem cell products, today announced that it expects to submit the Pre-Investigational New Drug (Pre-IND) document describing the suggested clinical trial and the preclinical data to the FDA by the end of the 4th quarter Of 2006. Approval of the Pre-IND by the FDA precedes initiation of Phase I trials.
Pluristem recently presented a Pre-Pre-IND to the Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapies, a department in the Food and Drug Administration (FDA). The Pre-Pre-IND documented the final results of an animal model study using the Company's innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells (PLX-I).
In the Pre-Pre-IND conference call following the submission of the document, the FDA team of experts and the Pluristem FDA team discussed the proposed structure of the clinical trial, and the pre-clinical data required to approve the initiation of Phase I clinical trials of PLX-I. The FDA and Pluristem agreed that the proposed structure of Pluristem's Phase I study should document the safe use of PLX-I cells when combined with Umbilical Cord Blood (UCB), and how the combination could improve the treatment of blood disorders.
In the upcoming Pre-IND filing, Pluristem will present to the FDA CBER team the results of an additional agreed upon pre-clinical Animal trial. This additional pre-clinical animal trial will be performed on immune-deficient irradiated NOD-SCID mice which will be co-implanted with un-purified human umbilical cord blood cells and PLX-I. The conclusions will be held in comparison to Pluristem's published Pre-clinical results that used CD34+ purified from human umbilical cord blood cells. This additional trial will determine the final structure of the pre-clinical data required for FDA approval of the IND application.
Mr. Zami Aberman, Pluristem CEO, stated: "We would like to thank the CBER team for the very productive discussion. We expect to demonstrate that the co-transplantation of PLX-I cell types are a promising manipulation that improves cord blood performance during the replacement of bone marrow transplants in adults. I believe that this new pre-clinical animal trial will help to finalize the required pre-clinical studies prior to moving to Phase I trials."
About Pluristem
Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product targets a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include statements: Pluristem expects to submit their Pre-Investigational New Drug (Pre-IND) Application to the Food and Drug Administration (FDA) by the end of the 4th Quarter, the FDA and Pluristem agreed that the proposed structure of Pluristem's Phase I study should document the safe use of PLX-I cells when combined with Umbilical Cord Blood (UCB), and how the combination could improve the treatment of blood disorders, in the upcoming Pre-IND filing, the additional trial will determine the final structure of the pre-clinical data required for FDA approval of the Pre-IND application, we expect to demonstrate that the co-transplantation of PLX-I cell types are a promising manipulation that improves cord blood performance during the replacement of bone marrow transplants in adults, that this new pre-clinical animal trial will help to finalize the required pre-clinical studies prior to moving to Phase 1 trials, the Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments, Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
SOURCE: Pluristem Life Systems, Inc.
Emerson Gerard Associates, Inc. Media Contact Jerry Jennings, 561-881-7318 mediareply*emersongerard.com or The PMH Group Investors Contact Paul Holm, 212-496-7238 pmhgroupinc*aol.com
Copyright Business Wire 2006
Posted by Fuzzy1018 on :
nice news, we should see a run today imo
Posted by R.A. on :
Yep...
Sorry I didn't notice there was already a thread, I just created another one.
But indeed, it's very nice news, it's coming off bottom + the news, it should be interesting for today.
Chart is nice as well.
Posted by Fuzzy1018 on :
gapping .02/.0209
Posted by Fuzzy1018 on :
.0205/.0209
Posted by Fuzzy1018 on :
.021/.0215
Posted by Fuzzy1018 on :
filled the gap, good point to get in imo
Posted by superman7 on :
had alot of buys into the close
this could be a play for tommorow
bought some at .0189(HOD) right at close, took a while to fill
Posted by superman7 on :
![[Roll Eyes]](rolleyes.gif)
![[Eek!]](eek.gif)
![[Smile]](smile.gif)